Bafna Pharmaceuticals (NSE:BAFNAPH) Cash-to-Debt: (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:BAFNAPH Bafna Pharmaceuticals Ltd NSE:BAFNAPH
58 GF Score
Price ₹323.50
GF Value ₹86.06
Valuation Significantly Overvalued
! 9 Warning Signs
View Full Analysis

What is Bafna Pharmaceuticals Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Bafna Pharmaceuticals's cash to debt ratio for the quarter that ended in Jun. 2026 was .

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Bafna Pharmaceuticals couldn't pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.

The historical rank and industry rank for Bafna Pharmaceuticals's Cash-to-Debt or its related term are showing as below:

NSE:BAFNAPH' s Cash-to-Debt Range Over the Past 10 Years
Min: 0   Med: 0.06   Max: 2.71
Current: 0.05

During the past 13 years, Bafna Pharmaceuticals's highest Cash to Debt Ratio was 2.71. The lowest was 0.00. And the median was 0.06.

NSE:BAFNAPH's Cash-to-Debt is ranked worse than
90.44% of 983 companies
in the Drug Manufacturers industry
Industry Median: 0.96 vs NSE:BAFNAPH: 0.05

Bafna Pharmaceuticals  (NSE:BAFNAPH) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Bafna Pharmaceuticals Cash-to-Debt Related Terms

Bafna Pharmaceuticals Cash-to-Debt Historical Data

* Premium members only.

The historical data trend for Bafna Pharmaceuticals's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

Bafna Pharmaceuticals Cash-to-Debt Chart

Bafna Pharmaceuticals Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cash-to-Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.02 0.34 0.06 0.12 0.05

Bafna Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cash-to-Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.01 - 0.05 -

NSE:BAFNAPH vs ZTS: Cash-to-Debt Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Bafna Pharmaceuticals's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bafna Pharmaceuticals Cash-to-Debt vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Bafna Pharmaceuticals's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Bafna Pharmaceuticals's Cash-to-Debt falls into.


NSE:BAFNAPH
58GF Score
Bafna Pharmaceuticals Ltd NSE:BAFNAPH
Cash-to-Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bafna Pharmaceuticals Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Bafna Pharmaceuticals's Cash to Debt Ratio for the fiscal year that ended in Mar. 2026 is calculated as:

Cash to Debt Ratio= Cash, Cash Equivalents, Marketable Securities / Total Debt
= Cash, Cash Equivalents, Marketable Securities / (Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation)
=20.245 / (196.511 + 177.822)
=0.05

Bafna Pharmaceuticals's Cash to Debt Ratio for the quarter that ended in Jun. 2026 is calculated as:

Do not have enough data to calculate Cash to Debt ratio.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Is Bafna Pharmaceuticals (NSE:BAFNAPH) Overvalued in 2026?

Based on GuruFocus' analysis, Bafna Pharmaceuticals stock appears to be overvalued. The current stock price of ₹323.50 is trading 275.9% above its estimated GF Value™ of ₹86.06. GuruFocus considers Bafna Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for NSE:BAFNAPH:

  • Cash-to-Debt:
  • GF Value™: ₹86.06 vs. price of ₹323.50 (275.9% above fair value)
  • GF Score™: 58/100 with 9 warning signs

No single metric tells the full story. See the NSE:BAFNAPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bafna Pharmaceuticals Business Description

Other Exchanges 532989:India
Address Thambu Chetty Street, New No. 68, Old No. 299, Bafna Towers, Chennai, TN, IND, 600001
Bafna Pharmaceuticals Ltd is an Indian pharmaceutical company mainly offering Contract Research and Manufacturing (CRAMS), Technology Transfers, Formulation, and Analytical Development services. It is engaged in the business of manufacturing finished pharmaceutical formulations, specializing in non-betalactam solid oral dosage forms, besides other emerging and potential products and forms in various therapeutic areas such as cardiology, lifestyle and potent drugs, and pain management. The company delivers generic pharmaceutical products for the UK, Australia, the EU, and emerging markets. In addition, it has launched its own brands in Sri Lanka, the Philippines, Tanzania, and Nigeria, offering products for some high-demand therapies like diabetes, cardiovascular, and oncology.
58GF Score

Get the complete analysis for NSE:BAFNAPH

Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹323.50
Price
₹86.06
GF Value